New hope for tough lung cancer: experimental drug ST-001 enters human testing
NCT ID NCT06922539
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This early-phase trial tests an experimental drug called ST-001 (a form of fenretinide) in people with small cell lung cancer that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and to watch for any side effects. About 44 participants will receive the drug through an IV for five days every three weeks. This study does not aim to cure the cancer but to see if the drug can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Southern California
RECRUITINGLos Angles, California, 90007, United States
Conditions
Explore the condition pages connected to this study.